...
首页> 外文期刊>Vaccine >Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD
【24h】

Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD

机译:通过鼻内施用表达糖蛋白gC或gD的复制缺陷型5型人腺病毒,诱导牛对1型牛疱疹病毒的保护性免疫

获取原文
获取原文并翻译 | 示例
           

摘要

Replication-defective human adenoviruses type 5 (HAd5) expressing the bovine herpesvirus type I (BHV-1) glycoprotein gC or gD under the control of the human cytomegalovirus immediate-early promoter/enhancer (AdCMVgC or AdCMVgD) or the 5' regulatory region of the human desmin gene (AdDESMgC or AdDESMgD) were generated. A preliminary experiment performed on rabbits showed that the intranasal administration of AdCMV elicited higher levels of BHV-1 neutralizing antibodies than the intramuscular administration of AdDESM. The obtained results allowed to select the replication-defective AdCMVgC and AdCMVgD for further assessment of their potential as a recombinant vaccine in cattle. Calves were injected intranasally twice 3 weeks apart with either AdCMVgC or AdCMVgD or a combination of these two recombinants or a commercially available live vaccine for comparison. The highest BHV-1 neutralizing antibody titres were obtained with AdCMVgD followed by the live vaccine and to a lower extent with the combination of the two recombinants (AdCMVgC + AdCMVgD). Calves were protected against intranasal BHV-1 challenge per-formed 3 weeks after the second immunization. In view of the obtained results, recombinant HAd5 may be developed as an intranasal vaccine vector in cattle administrated either alone or sequentially with non-human adenovirus-based vectors.
机译:在人巨细胞病毒即刻启动子/增强子(AdCMVgC或AdCMVgD)或5'调控区的控制下,表达I型牛疱疹病毒(BHV-1)糖蛋白gC或gD的复制缺陷型5型人类腺病毒(HAd5)。产生了人结蛋白基因(AdDESMgC或AdDESMgD)。在兔子身上进行的初步实验表明,与肌内给药相比,鼻内给药AdCMV引起的BHV-1中和抗体水平更高。获得的结果允许选择复制缺陷的AdCMVgC和AdCMVgD,以进一步评估它们作为牛重组疫苗的潜力。将小牛与AdCMVgC或AdCMVgD或这两种重组体的组合或市售活疫苗隔3周鼻内注射两次以进行比较。用AdCMVgD和随后的活疫苗可获得最高的BHV-1中和抗体效价,而两种重组体(AdCMVgC + AdCMVgD)的结合程度较低。第二次免疫3周后,对小牛进行了鼻内BHV-1攻击保护。鉴于所获得的结果,重组HAd5可以被开发为单独或与基于非人腺病毒的载体一起施用的牛的鼻内疫苗载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号